Lobeline

DB05137

small molecule investigational

Deskripsi

An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. PubChem

Struktur Molekul 2D

Berat 337.4553
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

121 Data
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Lobeline.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Lobeline.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Lobeline.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Lobeline.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Lobeline.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Lobeline.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Lobeline.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Lobeline.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Lobeline.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Lobeline.
Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Lobeline.
Propafenone The risk or severity of adverse effects can be increased when Propafenone is combined with Lobeline.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.
Nadolol The risk or severity of adverse effects can be increased when Nadolol is combined with Lobeline.
Bevantolol The risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.
Practolol The risk or severity of adverse effects can be increased when Practolol is combined with Lobeline.
Penbutolol The risk or severity of adverse effects can be increased when Penbutolol is combined with Lobeline.
Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Lobeline.
Dexpropranolol The risk or severity of adverse effects can be increased when Dexpropranolol is combined with Lobeline.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Lobeline.
Nebivolol The risk or severity of adverse effects can be increased when Nebivolol is combined with Lobeline.
Bufuralol The risk or severity of adverse effects can be increased when Bufuralol is combined with Lobeline.
Bopindolol The risk or severity of adverse effects can be increased when Bopindolol is combined with Lobeline.
Bupranolol The risk or severity of adverse effects can be increased when Bupranolol is combined with Lobeline.
Indenolol The risk or severity of adverse effects can be increased when Indenolol is combined with Lobeline.
Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Lobeline.
Levobetaxolol The risk or severity of adverse effects can be increased when Levobetaxolol is combined with Lobeline.
Talinolol The risk or severity of adverse effects can be increased when Talinolol is combined with Lobeline.
Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Lobeline.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline.
Esatenolol The risk or severity of adverse effects can be increased when Esatenolol is combined with Lobeline.
Cloranolol The risk or severity of adverse effects can be increased when Cloranolol is combined with Lobeline.
Mepindolol The risk or severity of adverse effects can be increased when Mepindolol is combined with Lobeline.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Lobeline.
Tertatolol The risk or severity of adverse effects can be increased when Tertatolol is combined with Lobeline.
Landiolol The risk or severity of adverse effects can be increased when Landiolol is combined with Lobeline.
Cimetropium Lobeline may decrease the anticholinergic activities of Cimetropium.
Pegvisomant The risk or severity of adverse effects can be increased when Pegvisomant is combined with Lobeline.
Mefloquine The risk or severity of adverse effects can be increased when Mefloquine is combined with Lobeline.
Tacrine The risk or severity of adverse effects can be increased when Tacrine is combined with Lobeline.
Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Lobeline.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Lobeline.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lobeline.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Lobeline.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Lobeline.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Lobeline.
Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Lobeline.
Pyridostigmine The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Lobeline.
Nizatidine The risk or severity of adverse effects can be increased when Nizatidine is combined with Lobeline.
Galantamine The risk or severity of adverse effects can be increased when Galantamine is combined with Lobeline.
Isoflurophate The risk or severity of adverse effects can be increased when Isoflurophate is combined with Lobeline.
Diethylcarbamazine The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Lobeline.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Lobeline.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Lobeline.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Lobeline.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Lobeline.
Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Lobeline.
Demecarium The risk or severity of adverse effects can be increased when Demecarium is combined with Lobeline.
Physostigmine The risk or severity of adverse effects can be increased when Physostigmine is combined with Lobeline.
Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Lobeline.
Edrophonium The risk or severity of adverse effects can be increased when Edrophonium is combined with Lobeline.
Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Lobeline.
Memantine The risk or severity of adverse effects can be increased when Memantine is combined with Lobeline.
Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with Lobeline.
Tubocurarine The risk or severity of adverse effects can be increased when Tubocurarine is combined with Lobeline.
Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Lobeline.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lobeline.
Decamethonium The risk or severity of adverse effects can be increased when Decamethonium is combined with Lobeline.
Pancuronium The risk or severity of adverse effects can be increased when Pancuronium is combined with Lobeline.
Pipecuronium The risk or severity of adverse effects can be increased when Pipecuronium is combined with Lobeline.
Ginkgo biloba The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Lobeline.
Neostigmine The risk or severity of adverse effects can be increased when Neostigmine is combined with Lobeline.
Bambuterol The risk or severity of adverse effects can be increased when Bambuterol is combined with Lobeline.
1,10-Phenanthroline The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Lobeline.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Lobeline.
Huperzine A The risk or severity of adverse effects can be increased when Huperzine A is combined with Lobeline.
Phenserine The risk or severity of adverse effects can be increased when Phenserine is combined with Lobeline.
Regramostim The risk or severity of adverse effects can be increased when Regramostim is combined with Lobeline.
Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with Lobeline.
Betaine The risk or severity of adverse effects can be increased when Betaine is combined with Lobeline.
Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with Lobeline.
Coumaphos The risk or severity of adverse effects can be increased when Coumaphos is combined with Lobeline.
Dichlorvos The risk or severity of adverse effects can be increased when Dichlorvos is combined with Lobeline.
Fenthion The risk or severity of adverse effects can be increased when Fenthion is combined with Lobeline.
Metrifonate The risk or severity of adverse effects can be increased when Metrifonate is combined with Lobeline.
Acotiamide The risk or severity of adverse effects can be increased when Acotiamide is combined with Lobeline.
Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Lobeline.
Paraoxon The risk or severity of adverse effects can be increased when Paraoxon is combined with Lobeline.
Tyrothricin The risk or severity of adverse effects can be increased when Tyrothricin is combined with Lobeline.
Ipidacrine The risk or severity of adverse effects can be increased when Ipidacrine is combined with Lobeline.
Distigmine The risk or severity of adverse effects can be increased when Distigmine is combined with Lobeline.
Tretamine The risk or severity of adverse effects can be increased when Tretamine is combined with Lobeline.
Posiphen The risk or severity of adverse effects can be increased when Posiphen is combined with Lobeline.
Methylphosphinic Acid The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Lobeline.
Capreomycin The therapeutic efficacy of Lobeline can be decreased when used in combination with Capreomycin.
Framycetin The therapeutic efficacy of Lobeline can be decreased when used in combination with Framycetin.
Amikacin The therapeutic efficacy of Lobeline can be decreased when used in combination with Amikacin.
Tobramycin The therapeutic efficacy of Lobeline can be decreased when used in combination with Tobramycin.
Gentamicin The therapeutic efficacy of Lobeline can be decreased when used in combination with Gentamicin.

Target Protein

Synaptic vesicular amine transporter SLC18A2
Neuronal acetylcholine receptor subunit alpha-7 CHRNA7
Neuronal acetylcholine receptor subunit alpha-9 CHRNA9
Neuronal acetylcholine receptor subunit alpha-10 CHRNA10

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17368966
    Miller DK, Lever JR, Rodvelt KR, Baskett JA, Will MJ, Kracke GR: Lobeline, a potential pharmacotherapy for drug addiction, binds to mu opioid receptors and diminishes the effects of opioid receptor agonists. Drug Alcohol Depend. 2007 Jul 10;89(2-3):282-91. Epub 2007 Mar 21.
  • PMID: 16825297
    Wu J, Liu Q, Yu K, Hu J, Kuo YP, Segerberg M, St John PA, Lukas RJ: Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors. J Physiol. 2006 Oct 1;576(Pt 1):103-18. Epub 2006 Jul 6.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul